Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics Inc has demonstrated significant progress in its clinical pipeline, particularly with the recent positive topline results from its DELIVER trial, which de-risked the safety profile of its candidate DYNE-251 for Duchenne Muscular Dystrophy, enhancing investor confidence. The company’s FORCE platform effectively addresses the challenges of delivering therapeutics to muscle tissue and the central nervous system, supporting a robust framework for future growth and potential FDA accelerated approvals. Furthermore, the firm's advancing programs and favorable data positions Dyne as an attractive acquisition target, contributing to an increased price target reflecting the elevated probability of success and overall positive sentiment in the market.

Bears say

Dyne Therapeutics Inc faces a negative outlook primarily due to a significant drop in patient numbers for key clinical endpoints, compounding concerns regarding the effectiveness and safety of its flagship therapies, specifically DYNE-101 and DYNE-251. The stock has been trading at a discount relative to competitors, influenced by apprehensions about the timeline and regulatory pathways for its diseases, particularly DM1, amid potential delays and market competition from other therapeutic developments. Additionally, the company's future revenue estimates may be adversely impacted if its clinical candidates fail to achieve necessary regulatory approvals or meet clinical trial endpoints, with innovation in treatment methods potentially threatening the competitiveness of its current offerings.

Dyne Therapeutics (DYN) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 15 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.